We are live on ! Find out more
ATRS

Antares Pharma, Inc.

Delisted

ATRS was delisted on the 23rd of May, 2022.

81 hedge funds and large institutions have $127M invested in Antares Pharma, Inc. in 2015 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 20

18% more capital invested

Capital invested by funds: $107M → $127M (+$19.2M)

7% less funds holding

Funds holding: 8781 (-6)

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

79% less call options, than puts

Call options by funds: $63K | Put options by funds: $294K

Holders
81
Holders Change
-6
Holders Change %
-6.9%
% of All Funds
2.16%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
7
Increased
28
Reduced
20
Closed
13
Calls
$63K
Puts
$294K
Net Calls
-$231K
Net Calls Change
+$51K
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
26
Wells Fargo
California
$517K +$93.9K +36,997 +24%
TA
27
Teachers Advisors
New York
$448K
Swiss National Bank
28
Swiss National Bank
Switzerland
$392K
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$365K +$72.3K +28,511 +27%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$321K +$57.5K +22,650 +24%
Citigroup
31
Citigroup
New York
$281K -$47.5K -18,734 -15%
GCP
32
GSA Capital Partners
United Kingdom
$277K +$161K +63,300 +162%
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$273K -$75.5K -29,775 -23%
TC
34
TFS Capital
Pennsylvania
$272K -$58.3K -22,965 -19%
MLICM
35
Metropolitan Life Insurance Company (MetLife)
New York
$271K -$1.09K -430 -0.4%
VOYA Investment Management
36
VOYA Investment Management
Georgia
$254K
NPC
37
National Planning Corporation
California
$248K -$10.1K -4,000 -4%
FMA
38
FNY Managed Accounts
New York
$244K +$228K +90,000 New
NFA
39
Nationwide Fund Advisors
Ohio
$230K -$11.9K -4,672 -5%
BA
40
BlackRock Advisors
Delaware
$213K +$28.6K +11,287 +17%
OC
41
Oppenheimer & Co
New York
$207K -$8.63K -3,400 -4%
State Board of Administration of Florida Retirement System
42
State Board of Administration of Florida Retirement System
Florida
$199K
AIG
43
American International Group
New York
$199K
Goldman Sachs
44
Goldman Sachs
New York
$175K -$89K -35,087 -35%
UBS AM
45
UBS AM
Illinois
$162K +$9.39K +3,700 +7%
Group One Trading
46
Group One Trading
Illinois
$144K +$31.2K +12,300 +30%
Commonwealth Equity Services
47
Commonwealth Equity Services
Massachusetts
$141K -$142K -56,000 -52%
Deutsche Bank
48
Deutsche Bank
Germany
$135K -$89.8K -35,409 -41%
Citadel Advisors
49
Citadel Advisors
Florida
$125K +$781 +308 +0.7%
CS
50
Credit Suisse
Switzerland
$122K -$124K -48,797 -52%

ATRS Hedge Fund Activity: Q1 2015 in Review

81 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2015, worth a combined $127M — up 18% from $107M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ATRS and 7 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 28 added.

The largest buyer was Deerfield Management, adding an estimated $10.1M. The largest seller was William Harris Investors, cutting an estimated $1.38M.

  • 81 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2015, down from 87 in Q4 2014.
  • Funds reported $127M of Antares Pharma, Inc. stock for Q1 2015, up 18% quarter-over-quarter.
  • 7 funds opened new Antares Pharma, Inc. positions in Q1 2015 and 13 closed out, a net change of -6 holders.
  • The largest Antares Pharma, Inc. buyer in Q1 2015 was Deerfield Management, an estimated $10.1M added.
  • The largest Antares Pharma, Inc. seller in Q1 2015 was William Harris Investors, an estimated $1.38M sold.

Based on aggregated 13F filings for Q1 2015.